This site is intended for healthcare professionals
Abstract digital waveforms in blue and purple
FDA Drug information

Meloxicam

Read time: 1 mins
Marketing start date: 23 Dec 2024
...
 

Summary of product characteristics


Effective Time

20221018

Version

7

Spl Product Data Elements

meloxicam meloxicam MELOXICAM MELOXICAM CROSPOVIDONE (15 MPA.S AT 5%) LACTOSE MONOHYDRATE MAGNESIUM STEARATE MICROCRYSTALLINE CELLULOSE 101 POVIDONE K30 SILICON DIOXIDE TRISODIUM CITRATE DIHYDRATE YELLOW ROUND ZC;25 meloxicam meloxicam MELOXICAM MELOXICAM CROSPOVIDONE (15 MPA.S AT 5%) LACTOSE MONOHYDRATE MAGNESIUM STEARATE SILICON DIOXIDE TRISODIUM CITRATE DIHYDRATE POVIDONE K30 MICROCRYSTALLINE CELLULOSE 101 YELLOW ROUND ZC;26

Application Number

ANDA077921

Brand Name

Meloxicam

Generic Name

meloxicam

Product Ndc

65841-051

Product Type

HUMAN PRESCRIPTION DRUG

Route

ORAL

Package Label Principal Display Panel

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL NDC 65841-050-01 in bottle of 500 tablets Meloxicam Tablets USP, 7.5 mg R x only 500 tablets NDC 65841-051-01 in bottle of 500 tablets Meloxicam Tablets USP, 15 mg R x only 500 tablets Meloxicam Tablets, 7.5 mg Meloxicam Tablets, 15 mg

Spl Medguide

SPL MEDGUIDE Manufactured by: Cadila Healthcare Ltd. India.

Drug section

CME banner

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Disclaimer

The drug Prescribing Information (PI), including indications, contra-indications, interactions, etc, has been developed using the U.S. Food & Drug Administration (FDA) as a source (www.fda.gov).

Medthority offers the whole library of PI documents from the FDA. Medthority will not be held liable for explicit or implicit errors, or missing data.

Drugs appearing in this section are approved by the FDA. For regions outside of the United States, this content is for informational purposes only and may not be aligned with local regulatory approvals or guidance.